BioSpace News Archive

ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Jennifer L. Herron has been appointed to the Board as an independent director, effective June 28, 2022.

AAVHSC16 Biodistribution Properties in Preclinical Models Demonstrated Potential for Systemic Delivery of Genetic Medicines to Brain, Heart and Muscle.

PharmaCyte Biotech, Inc. today announced the results of a study to determine whether a previous established quantitative real-time PCR ( qRT-PCR) could be used as a quality control test for its CypCaps™ product candidate.

Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company focused on transforming the treatment of kidney disease, today announced that the Company has entered into a research collaboration with the University of Michigan at Ann Arbor (U-M).

Brand Institute is proud to announce its work with Solasia Pharma K.K. (“Solasia”) in developing the brand name DARVIAS®.

Current Patents and Planned Future Patent Applications Covers the Company’s Lead Product Candidate, PRP, and Backup Clinical Compounds.

Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, July 28, 2022.

Sanara MedTech Inc . Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today that it closed the acquisition of Scendia Biologics, LLC (“Scendia”) on July 1, 2022.

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA” or the “Agency”) has informed the Company that the Agency is planning to reconvene the Peripheral and Central Nervous System Drugs Advisory Committee (PCNSDAC) to discuss the New Drug Application (NDA) for AMX0035 (sodium phenylbutyrate [PB].

Innovaderm, a leading CRO in dermatology, has expanded its biometrics capacity following the acquisition of Excelsus Statistics, a Montreal-based company specialized in biostatistical and SAS programming services with a special expertise in adaptive trial design, as well as activities in many different therapeutic areas.